Heart:Fontan循环患者的晚期死亡模式

2020-03-04 xiangting MedSci原创

在检测大多数有晚期死亡风险的患者时,常规临床监测并不敏感。一半的晚期死亡是Fontan循环衰竭造成的。

Fontan循环患者的机体损害机制尚未明确,一些死亡是否可以预防也不清楚。这项研究分析了Fontan循环患者的晚期死亡情况,特别侧重于确定导致循环功能下降并可进行干预的病变。

1975年至2018年间,共有105例来自两国登记的患者完成Fontan手术1年后死亡,中位年龄为18.6岁(IQR 13.8-26.0),死亡时间为完成手术后12.7年(IQR 6.0-19.3)。

共有105例患者死亡,其中63例患者(60%)为心房肺动脉(AP)Fontan,21例(20%)为侧通道(LT),21例(20%)为心外管道(ECC)。72例患者(69%)在死亡前2年内进行了检查,其中32%(23/72)被认为是临床良好。Fontan循环衰竭是42例患者最常见的死因(45%)。其他死因包括猝死/心律失常(19%)、围手术期死亡(12%)、神经系统并发症(7%)和血栓栓塞(7%)。死于Fontan衰竭的所有LT或ECC患者在死亡时至少有1个可进行干预的手术缺陷。

在检测大多数有晚期死亡风险的患者时,常规临床监测并不敏感。一半的晚期死亡是Fontan循环衰竭造成的。临床表现为循环衰竭的LT或ECC Fontan循环死者,可能有潜在的可纠正病灶。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1699976, encodeId=14f116999e62b, content=<a href='/topic/show?id=e720e583c0' target=_blank style='color:#2F92EE;'>#Fontan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7583, encryptionId=e720e583c0, topicName=Fontan)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=284729986400, createdName=changjitao2019, createdTime=Wed Oct 07 18:46:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746952, encodeId=6ef01e4695207, content=<a href='/topic/show?id=390ae585da' target=_blank style='color:#2F92EE;'>#Fontan循环#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7585, encryptionId=390ae585da, topicName=Fontan循环)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a9035886041, createdName=zgwhgch, createdTime=Sun Mar 22 10:46:00 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357423, encodeId=8a09135e423a2, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 06 04:46:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563248, encodeId=050b1563248b6, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Mar 06 04:46:00 CST 2020, time=2020-03-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1699976, encodeId=14f116999e62b, content=<a href='/topic/show?id=e720e583c0' target=_blank style='color:#2F92EE;'>#Fontan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7583, encryptionId=e720e583c0, topicName=Fontan)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=284729986400, createdName=changjitao2019, createdTime=Wed Oct 07 18:46:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746952, encodeId=6ef01e4695207, content=<a href='/topic/show?id=390ae585da' target=_blank style='color:#2F92EE;'>#Fontan循环#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7585, encryptionId=390ae585da, topicName=Fontan循环)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a9035886041, createdName=zgwhgch, createdTime=Sun Mar 22 10:46:00 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357423, encodeId=8a09135e423a2, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 06 04:46:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563248, encodeId=050b1563248b6, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Mar 06 04:46:00 CST 2020, time=2020-03-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1699976, encodeId=14f116999e62b, content=<a href='/topic/show?id=e720e583c0' target=_blank style='color:#2F92EE;'>#Fontan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7583, encryptionId=e720e583c0, topicName=Fontan)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=284729986400, createdName=changjitao2019, createdTime=Wed Oct 07 18:46:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746952, encodeId=6ef01e4695207, content=<a href='/topic/show?id=390ae585da' target=_blank style='color:#2F92EE;'>#Fontan循环#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7585, encryptionId=390ae585da, topicName=Fontan循环)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a9035886041, createdName=zgwhgch, createdTime=Sun Mar 22 10:46:00 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357423, encodeId=8a09135e423a2, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 06 04:46:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563248, encodeId=050b1563248b6, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Mar 06 04:46:00 CST 2020, time=2020-03-06, status=1, ipAttribution=)]
    2020-03-06 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1699976, encodeId=14f116999e62b, content=<a href='/topic/show?id=e720e583c0' target=_blank style='color:#2F92EE;'>#Fontan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7583, encryptionId=e720e583c0, topicName=Fontan)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=284729986400, createdName=changjitao2019, createdTime=Wed Oct 07 18:46:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746952, encodeId=6ef01e4695207, content=<a href='/topic/show?id=390ae585da' target=_blank style='color:#2F92EE;'>#Fontan循环#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7585, encryptionId=390ae585da, topicName=Fontan循环)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a9035886041, createdName=zgwhgch, createdTime=Sun Mar 22 10:46:00 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357423, encodeId=8a09135e423a2, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Mar 06 04:46:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563248, encodeId=050b1563248b6, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Mar 06 04:46:00 CST 2020, time=2020-03-06, status=1, ipAttribution=)]
    2020-03-06 slcumt

相关资讯

2019 CSANZ立场声明:Fontan循环患者的管理

2019年11月,澳大利亚和新西兰心脏学会(CSANZ)发布了Fontan循环患者的管理声明,主要目的是为Fontan循环患者的管理提供共识意见。

Heart:Fontan循环中使用开窗术作为慢性心脏保护的策略

与NC-F患者相比,P-F患者具有稳健的血流动力学,并且前负荷储备安全、后负荷减少、β-肾上腺素能反应抑制以及基线HR较低。

2019 AHA科学声明:儿童和成人Fontan循环的评估和管理

2019年7月,美国心脏协会(AHA)发布了儿童和成人Fontan循环的评估和管理声明,文章主要总结了当前Fontan循环的最新信息,并针对接受Fontan循环患者的随访及其并发症的管理达成共识。